Gastrointestinal stromal tumors (GIST)
Gastrointestinal stromal tumors (GIST) are relatively rare, but the rate of incidence has been steadily rising. In the past, the only way to contend with these tumors had been extensive surgery in the abdominal cavity. Today, after scientists succeeded in deciphering the genetic code of the tumor’s biological behavior, GIST may be treated with innovative drugs that use a unique biological mechanism to suppress tumor development.
Currently, Oncotest offers tests for all stages of GIST:
The stage deciding on the initial treatment: today it is possible to prepare the most suitable dose according to the genomic profile obtained from C-Kit receptor test, which characterizes the genetics of the disease.
The stage of resistance to treatment: in instances of the development of resistance to the effective biological treatment fighting GIST, the source of the resistance may be identified using Oncotest tests and treatment may be customized according to the test results.
Monitoring the tumor progression using liquid tests that depict the sections of DNA of the tumor in the blood flow and detect early-stage resistance. In this way, it is possible to accurately identify the type of resistance that developed and adjust the early-stage treatment.